natgillin/translations-raw huggingface dataset:
Preglednica 4: Povzetek rezultatov kliničnega odziva v 1. študiji psoriaze (PHOENIX 1) in v 2. študiji psoriaze (PHOENIX 2)
Table 4 Summary of clinical response in Psoriasis Study 1 (PHOENIX 1) and Psoriasis Study 2 (PHOENIX 2)
Preglednica 4: Rezultati učinkovitosti (pri raku dojke in multiplem mielomu)
Efficacy results are provided in Table 4.
Preglednica 4: Spremembe odmerkov zdravila Teysuno in cisplatina glede na vrednosti očistka kreatinina na začetku cikla zdravljenja
Table 4: Teysuno and cisplatin dose modification according to creatinine clearance values at the start of a cycle of treatment
Preglednica 4: Vzdrževanje kliničnega odziva in klinične remisije v študiji IM-UNITI (44 tednov; 52 tednov od indukcijskega odmerka)
Table 4: Maintenance of Clinical Response and Remission in IM-UNITI (week 44; 52 weeks from initiation of the induction dose)
Preglednica 5 Povzetek rezultatov kliničnega odziva po 12 tednih v 3. študiji psoriaze (ACCEPT)
Table 5 Summary of clinical response at week 12 in Psoriasis Study 3 (ACCEPT)
Preglednica 5.
Table 5.
Preglednica 5: Delež bolnikov s popolnim odzivom po dnevih v združenih raziskavah TIH
Table 5: Proportion of complete responders by day in the combined TIH studies
Preglednica 5: Hematološka toksičnost, zaradi katere se zdravljenje z zdravilom Teysuno ukine
Table 5: Haematologic toxicities for which Teysuno treatment should be suspended
Preglednica 6 Število bolnikov, ki so v 1. študiji psoriatičnega artritisa (PSUMMIT I) in v 2. študiji psoriatičnega artritisa (PSUMMIT II) po 24 tednih dosegli klinični odziv
Table 6 Number of patients who achieved clinical response in Psoriatic arthritis Study 1 (PSUMMIT I) and Study 2 (PSUMMIT II) at week 24
Preglednica 6: Minimalna merila za nadaljevanje zdravljenja z zdravilom Teysuno, ki sledi ukinitvi zdravila zaradi toksičnosti
Table 6: Minimum criteria to resume Teysuno treatment following its suspension due to a toxicity
Preglednica 7: Neželeni učinki, navedeni po padajoči resnosti znotraj vsake skupine pogostnosti
Table 7: Adverse reactions reported by decreasing seriousness in each frequency grouping
Preglednica 7: povzetek primarnih in sekundarnih ciljev v 12. in 52. tednu
Table 7 Summary of primary and secondary endpoints at week 12 and week 52
Preglednica 8: Demografske in izhodiščne značilnosti bolnikov v študiji FLAGS
Table 8: Demographics and baseline characteristics of patients in the FLAGS study
Preglednica 9: Celokupno preživetje in preživetje brez napredovanja bolezni v študiji FLAGS
Table 9: Overall survival and progression-free survival in FLAGS
Preglednici 1 in 2 kažeta pogostnost neželenih učinkov v s placebom nadzorovanih kliničnih preskušanjih pri Parkinsonovi bolezni in drugih indikacij.
Tables 1 and 2 display the frequency of adverse drug reactions from placebo-controlled clinical trials in Parkinson’s disease and another indication.
Prehľad bezpečnostného profilu
Summary of the safety profile
Preiskava
Investigation
Preizkusi so pokazali, da suhe mešanice dušikovega oksida lahko uporabljamo z večino materialov.
Tests show that dry nitric oxide mixtures can be used with most materials.
Prejeli boste dodaten kalcij in vitamin D v ustreznem odmerku.
You will be given adequate calcium and vitamin D supplements.
Prejemniki 4 mg zoledronske kisline so navajali manjši porast bolečin kot prejemniki placeba in razlika je bila značilna 3., 9., 21. in 24. mesec.
Patients receiving zoledronic acid 4 mg reported less increase in pain than those receiving placebo, and the difference reached significance at months 3, 9, 21 and 24.
Prejmete lahko tudi drugo zdravljenje z lasersko svetlobo 96-120 ur po začetnem vbrizganem odmerku PhotoBarra.
You may receive a second laser light treatment 96-120 hours after the initial injection of PhotoBarr.
Prek tega mehanizma fenofibrat pospeši lipolizo in odstranjevanje delcev, bogatih s trigliceridi, iz plazme, tako da aktivira lipoproteinsko lipazo in zmanjša produkcijo apoproteina C–III.
Through this mechanism, fenofibrate increases lipolysis and elimination of triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III.
Prekinitev je treba opraviti vsaj 12 ur po stabilizaciji bolnika z majhnim odmerkom zdravila INOmax.
Weaning should be attempted at least every 12 hours when the patient is stable on a low dose of INOmax.
Prekinitev zdravljenja
Discontinuation of therapy
Prekinitev zdravljenja z inhalacijskim dušikovim oksidom je treba opraviti po korakih.
The withdrawal of inhaled nitric oxide therapy should be performed in a stepwise manner.
Prekinitev zdravljenja:
Treatment discontinuation
Prekliinilised ohutusandmed
Preclinical safety data
Preklinický výzkum naznačuje, že guanfacin moduluje signály v prefrontálním kortexu a v bazálních gangliích přímou modifikací transmise synaptického noradrenalinu na alfa2-adrenergních receptorech.
Preclinical research suggests guanfacine modulates signalling in the prefrontal cortex and basal ganglia through direct modification of synaptic noradrenalin transmission at the alpha 2- adrenergic receptors.
Prekliniska säkerhetsuppgifter
PHARMACEUTICAL PARTICULARS
Prekliniska säkerhetsuppgifter
Preclinical safety data
premenjeno ali povečano spolno zanimanje in vedenje, ki vam ali drugim povzroča znatno zaskrbljenost, na primer povečan libido*;
Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive.
prenajedanje (uživanje velikih količin hrane v kratkem obdobju) ali kompulzivno uživanje hrane (uživanje večjih količin hrane od normalnih in več, kot je potrebno za potešitev lakote)*,
Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)
Prenehajte dojiti še preden pričnete z zdravljenjem z zdravilom Topotekan Teva. če imate prenizko število krvnih celic;
You should stop breast-feeding before starting treatment with Topotecan Teva; if your blood cells count is too low.
Preobčutljivost
Hypersensitivity
Preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, nevedno v poglavju 6.1.
Hypersensitivity to the active substance or to any of the excipients listed in section 2 or section 6.1.
Preobčutljivost na zdravilno učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Preobčutljivost za lateks
Latex sensitivity
Preobčutljivost za zdravilne učinkovine (tegafur, gimeracil in oteracil) ali katero koli pomožno snov, navedeno v poglavju 6.1.
Hypersensitivity to any of the active substances (tegafur, gimeracil, and oteracil) or to any of the excipients listed in section 6.1.
Preobčutljivost za zdravilne učinkovine (tegafur, gimeracil in oteracil) ali katero koli pomožno snov, navedeno v poglavju in 6.1.
Hypersensitivity to any of the active substances (tegafur, gimeracil, and oteracil) or to any of the excipients listed in 6.1.
Preobčutljivost za zdravilni učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1.
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Preobčutljivost za zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1. Dojenje (glejte poglavje 4.6).
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Breast-feeding (see section 4.6).
Preobčutljivost za zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1. Klinično pomembna, aktivna okužba (npr. aktivna tuberkuloza; glejte poglavje 4.4).
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Clinically important, active infection (e.g. active tuberculosis; see section 4.4).
Preobčutljivost za zdravilno učinkovino, druge porfirine ali katero koli pomožno snov.
Hypersensitivity to the active substance, other porphyrins or to any of the excipients.
Preobčutljivost za zdravilno učinkovino, za druge difosfonate ali katero koli pomožno snov, navedeno v poglavju 6.1
Hypersensitivity to the active substance, to other bisphosphonates or to any of the excipients listed in section 6.1
preobčutljivost, pruritus, izpuščaj
hypersensitivity, pruritus, rash
Preobčutljivostna reakcija Angionevrotični edem
Hypersensitivity reaction Angioneurotic oedema
Preobčutljivostne in infuzijske reakcije
Hypersensitivity and infusion reactions
Preobčutljivostne reakcije
Hypersensitivity reactions
Preobčutljivostne reakcije.
Hypersensitivity reactions.
Preotact 100 микрограма прах и разтворител за инжекционен разтвор в предварително напълнена писалка
Preotact 100 micrograms powder and solvent for solution for injection in a pre-filled pen
Preotact 100 микрограма прах и разтворител за инжекционен разтвор в предварително напълнена писалка
Preotact 100 micrograms powder and solvent for solution for injection in a pre-filled pen.
Preotact 100 микрограма прах и разтворител за инжекционен разтвор в предварително напълнена писалка Паратиреоиден хормон
Preotact 100 micrograms powder and solvent for solution for injection Parathyroid hormone
Preotact е прилаган в единократни дози до 5 микрограма/kg и в многократни дози до 3 микрограма/kg/ден в продължение на 3 дни до 2,5 микрограма/kg/ден в продължение на 7 дни.
Preotact has been administered in single doses up to 5 micrograms/kg and in repeated doses of up to 3 microgramskgday for 3 days and up to 2.5 microgramskgday for 7 days.
Preotact може да се прилага до 24 месеца, след което пациентите могат да бъдат лекувани с бифосфонат (лекарство, което намалява загубата на костна маса).
Preotact can be used for up to 24 months, after which patients can be treated with a bisphosphonate (a medicine that reduces bone loss).
Preotact не трябва да се използва при деца и юноши под 18-годишна възраст.
Preotact should not be used in children or adolescents under 18 years old.
Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals 3,75 µg суспензия за инжекционна емулсия
Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals 3.75 µg suspension for emulsion for injection
Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals 3,75 µg суспензия и емулсия за инжекционна емулсия
Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals 3.75 µg suspension and emulsion for emulsion for injection
Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals 3,75 g се състои от две опаковки:
Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals 3.75 µg consists of two containers:
Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals е ваксина срещу предпандемичен грип.
Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals is a ‘prepandemic’ vaccine.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics е ваксина за приложение при възрастни (от 18 до 60 години) и лица в старческа възраст (над 60 години).
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics is a vaccine for use in adults (from 18 to 60 years old). and elderly (over 60 years old).
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics е ваксина.
Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics is a vaccine.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics е противопоказан за пациенти, които са проявили анафилактична реакция (тежка алергична реакция) към някоя от съставките на ваксината, включително към съставки, съдържащи се в много малки количества във ваксината, например яйчен и пилешки протеин, овалбумин (протеин в яйчния белтък), канамицин или неомицин сулфат (антибиотици), формалдехид и цетилтриметиламониум бромид.
Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics should not be given to patients who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, including those found at trace (very low levels) such as egg or chicken protein, ovalbumin (a protein in egg white), kanamycin or neomycin sulphate (antibiotics), formaldehyde and cetyltrimethylammonium bromide.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics е „предпандемична“ ваксина.
Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics is a ‘prepandemic’ vaccine.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics инжекционна суспензия в предварително напълнена спринцовка
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics suspension for injection in pre-filled syringe.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics инжекционна суспензия в предварително напълнена спринцовка Ваксина срещу предпандемичен грип (H5N1) (повърхностен антиген, инактивиран, с адювант) (Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted))
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics suspension for injection in pre-filled syringe Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics може да се прилага при налична имунна недостатъчност, но е възможно да не бъде предизвикана защитна имунна реакция.
in the presence of immune deficiencies Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics may be administered but a protective immune response may not be elicited.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics представлява инжекционна суспензия в предварително напълнена спринцовка.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics is a suspension for injection in a pre-filled syringe.
Prepandrix е ваксина за приложение при възрастни лица на 18 и повече години.
Prepandrix is a vaccine for use in adults from 18 years old.
Prepandrix е ваксина за профилактика на грип, причинен от щам (тип) H5N1 на грипния вирус А. Prepandrix се прилага съгласно официалните препоръки.
Prepandrix is given according to official recommendations.
Prepandrix е „предпандемична“ ваксина.
Prepandrix is a ‘prepandemic’ vaccine.
Prepandrix суспензия и емулсия за инжекционна емулсия
Prepandrix suspension and emulsion for emulsion for injection
Prepandrix суспензия и емулсия за инжекционна емулсия
Prepandrix suspension and emulsion for emulsion for injection.
Prepandrix съдържа грипния щам ‘A/Indonesia/05/2005’ (H5N1).
Prepandrix contains a flu strain called ‘A/Indonesia/05/2005’ (H5N1).
Preprečevanje aterotrombotičnih in trombemboličnih dogodkov pri atrijski fibrilaciji
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation
Preprečevanje pooperativne navzee in bruhanja (Post Operative Nausea and Vomiting – PONV): Opravili so dve pediatrični preskušanji.
Prevention of Post Operative Nausea and Vomiting (PONV):
Preprečevanje s kemoterapijo povzročene navzee inbruhanja (Chemotherapy Induced Nausea and Vomiting – CINV):
Prevention of Chemotherapy Induced Nausea and Vomiting (CINV):
Preprečevanje z okostjem povezanih dogodkov pri bolnikih z napredovalimi malignimi boleznimi, ki zajamejo kosti:
Prevention of skeletal related events in patients with advanced malignancies involving bone:
Prepričajte se: da sta število vial in odmerek pravilna.
Check the vial(s) to make sure: the number of vials and strength is correct
PRES трябва да се има предвид при всеки пациент с гърчове, главоболие, зрителни нарушения, объркване или изменена психична функция.
PRES should be considered in any patient presenting with seizures, headache, visual disturbances, confusion or altered mental function.
PRES, наричан по-рано синдром на обратима постериорна левкоенцефалопатия (reversible posterior leukoencephalopathy syndrome, RPLS), е рядко неврологично нарушение, което може да се прояви с гърчове, главоболие, сънливост, объркване, слепота, нарушено съзнание и други зрителни и неврологични нарушения, придружени с хипертония, а диагнозата се потвърждава с образно изследване на нервната система.
PRES, formerly termed reversible posterior leukoencephalopathy syndrome (RPLS), is a rare, neurological disorder, which can present with seizure, headache, lethargy, confusion, blindness, altered consciousness, and other visual and neurological disturbances, along with hypertension, and the diagnosis is confirmed by neuro-radiological imaging.
PreSAP проучването не показа статистически значимо увеличение на риска за същата комбинирана крайна точка.
The PreSAP trial did not demonstrate a statistically significant increased risk for the same composite endpoint.
Preskušanje INOT25, ki je preučevalo učinke iNO pri hipoksičnih nedonošenčkih, ni pokazalo izboljšanja glede živih novorojenčkov brez BPD.
The INOT25 trial, studying the effects of iNO in hypoxic preterm neonates, did not show improvement in alive without BPD.
Presnavljanje
Metabolism
Presnova predstavlja < 10 % izločanja topotekana.
Metabolism accounts for <10 % of the elimination of topotecan.
Presnovek, ki nastaja v največji količini, je 8-hidroksi-ibafloksacin, ki je tudi mikrobiološko aktiven.
The most abundant metabolite is 8-hydroxy-ibafloxacin, which is also microbiologically active . lbafloxacin and 8- hydroxy-ibafloxacin act synergistically.
Presnovek, ki nastaja v največji količini, je 8-hidroksi-ibafloksacin, ki je tudi mikrobiološko aktiven.
The most abundant metabolite is 8-hydroxy-ibafloxacin, which is also microbiologically active. lbafloxacin and 8- hydroxy-ibafloxacin act synergistically.
Presnovki folinata/folinske kisline oblikujejo trikomponentno zmes s timidilatno sintazo in fluorodeoksiuridin monofosfatom (FdUMP), kar lahko poveča citotoksičnost snovi 5-FU.
However, metabolites of folinate/folinic acid will form a ternary structure with thymidylate synthase and fluorodeoxyuridine monophosphate (FdUMP), potentially increasing the cytotoxicity of 5-FU.
Presnovne in prehranske motnje
Metabolism and nutrition disorders
PRETISNI OMOT
BLISTER
PRETISNI OMOT (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ali 100x1 filmsko obložene tablete)
BLISTER (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablets)
PRETISNI OMOT (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 filmsko obložena tableta)
BLISTER (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet)
Pretisni omot aluminij-aluminij
Blister-alu/alu
PRETISNI OMOTI
BLISTERS
Preto ak je to možné, súbežnému užívaniu trabektedínu so silnými induktormi CYP3A4 (napr. rifampicín, fenobarbital, ľubovník bodkovaný) sa má predísť (pozri časť 4.4).
Therefore, the concomitant use of trabectedin with strong CYP3A4 inducers (e.g., rifampicin, phenobarbital, Saint John’s Wort) should be avoided if possible (see section 4.4).
Preto sa bežne neodporúčajú úpravy dávkovania výhradne na základe vekových kritérií.
Therefore, dose adjustments based uniquely on age criteria are not routinely recommended.
Preto sa dá pomer extrakcie trabektedínu považovať za mierny.
Thus the trabectedin extraction ratio can be considered moderate.
pretrganjem, ščemenje in otrplost (periferna polinevropatija).
Tingling and numbness (peripheral polyneuropathy).
Preudarno je prihraniti uporabo fluorokinolonov za zdravljenje kliničnih stanj, ki se slabo odzivajo ali za katera pričakujemo, da se bodo slabo odzivala na druge skupine antibiotikov.
It is prudent to reserve the fluoroquinolones for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antibiotic.
Preudarno je prihraniti uporabo fluorokinolonov za zdravljenje kliničnih stanj, ki se slabo odzivajo ali za katera pričakujemo, da so bodo slabo odzivala na druge skupine antibiotikov.
It is prudent to reserve the fluoroquinolones for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antibiotic.
Prevalenca alelov CYP2C19, ki povzročijo srednjo ali slabo presnovo s CYP2C19, se razlikuje glede na raso/etnično pripadnost (glejte Farmakogenetika).
The prevalence of CYP2C19 alleles that result in intermediate and poor CYP2C19 metabolism differs according to race/ethnicity (see Pharmacogenetics).
prevelika zaspanost podnevi in nenaden nepremagljiv spanec,
Excessive daytime sleepiness and suddenly falling asleep
prevelika zaspanost podnevi in nenaden spanec,
Excessive daytime sleepiness and suddenly falling asleep
Preveliki odmerki klopidogrela lahko podaljšajo čas krvavitve in posledično povzročijo zaplete s krvavitvijo.
Overdose following clopidogrel administration may lead to prolonged bleeding time and subsequent bleeding complications.
Preveliko odmerjanje
Overdose
Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če je potrebno)
Overdose (symptoms, emergency procedures, antidotes), if necessary
Preveliko odmerjanje zdravila INOmax se kaže s povečanjem methemoglobina in NO2.
Overdose with INOmax will be manifest by elevations in methaemoglobin and NO2.
Preveliko odmerjanje‌‌
Overdose
Preveliko odmerjanje‌‌
Overdose‌‌
Preveliko zanašanje na eno skupino antibiotikov lahko privede do odpornosti bakterijske populacije.
Heavy reliance on a single class of antibiotic may result in the induction of resistance in a bacterial population.
Preveliko zanašanje na eno skupino antibiotikov lahko privede do odpornosti populacije bakterij.
Heavy reliance on a single class of antibiotic may result in the induction of resistance in a bacterial population.
Prevenar 13 --1
Prevenar 13
Prevenar 13 води до сравними, макар и малко по-ниски нива на антителата, отколкото Prevenar за 7-те обичайни серотипа.
Prevenar 13 elicited comparable, although slightly lower, antibody levels than Prevenar for the 7 common serotypes.
Prevenar 13 е стабилен при стайна температура до 25°C в продължение на четири дни.
Prevenar 13 is stable at temperatures up to 25°C for four days.
Prevenar 13 е стабилен при температури до 25ºC в продължение на четири дни.
Prevenar 13 is stable at temperatures up to 25°C for four days.
Prevenar 13 инжекционна суспензия
Prevenar 13 suspension for injection
Prevenar 13 инжекционна суспензия i.m.
Prevenar 13 suspension for injection IM
Prevenar 13 инжекционна суспензия в еднодозов флакон
Prevenar 13 suspension for injection in single dose vial
Prevenar 13 инжекционна суспензия в еднодозов флакон i.m.
Prevenar 13 suspension for injection in single dose vial IM
Prevenar 13 се използва за защита на деца на възраст между шест седмици и 17 години от инвазивно заболяване, пневмония (инфекция на белите дробове) и остро възпаление на средното ухо, причинено от S.pneumoniae.
Prevenar 13 is used to protect children aged between six weeks and 17 years against invasive disease, pneumonia (infection of the lungs) and acute otitis media (infection of the middle ear) caused by
Prevenar 13 спрямо PPSV23,
Prevenar 13 Relative to PPSV23,
Prevenar 13 съдържа малки количества полизахариди (вид захари), извлечени от „капсулата“, която огражда бактерията S.pneumoniaе.
Prevenar 13 contains small amounts of polysaccharides (a type of sugar) extracted from the ‘capsule’ that surrounds the S. pneumoniae bacterium.